Extended cycles with the combined oral contraceptive chlormadinone acetate 2mg/ethinylestradiol 0.03mg: Pooled analysis of data from three large-scale, non-interventional, observational studies

Clinical Drug Investigation

Volumn 31, Issue 4, 2011, Pages 269-277

  Göretzlehner, Gunther ^a   Waldmann Rex, Susanne ^b   Schramm, Georg A K ^b  

^a not available   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; CHLORMADINONE ACETATE; DRUG DERIVATIVE; ETHINYLESTRADIOL; ETHINYLESTRADIOL CHLORMADINONE ACETATE; ETHINYLESTRADIOL-CHLORMADINONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BODY WEIGHT; CONCENTRATION LOSS; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; LIBIDO DISORDER; METRORRHAGIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; WEIGHT GAIN; WITHDRAWAL BLEEDING; ADULT; DRUG EFFECT; MENSTRUAL CYCLE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE;

EID: 79955782384     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11586720-000000000-00000     Document Type: Article

References (27)

1. Maix-Studie, Grunenthal GmbH. Langzyklus: Anwendung von oralen Kontrazeptiva. Bundesweite Erhebung bei 1 743 Gynäkologen. Frauenarzt 2004; 45 Suppl.: 1-7
2. Göretzlehner G. Langzyklus: orale Ovulationshemmer als Mikropillen ohne Pause. J Reproduktionsmed Endokrinol 2007; 4: 140-2 (Pubitemid 47400893)
3. Edelman A, Gallo MF, Nichols MD, et al. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006; 21: 573-8 (Pubitemid 43372958)
4. Guilbert E, Boroditsky R, Black A, et al. Canadian consensus guideline on continuous and extended hormonal contraception. J Obstet Gynaecol Can 2007; 29 Suppl. 2: 1-32
5. Wiegratz I, Hommel HH, Zimmermann T, et al. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69: 37-42 (Pubitemid 38076964)
6. Gille G. Menstruationsperzeption und Langzyklus. Gynä- kologe 2005; 38: 817-26 (Pubitemid 41367391)
7. Lürke A. Langzyklus in der Diskussion: das Erleben der Menstruation ist für junge Mädchen wichtig. Gyn 2006; 11: 358-60
8. Birkhäuser M, Braendle W, Breckwoldt M, et al. Zürcher Gesprächskreis: Empfehlungen zur oralen Kontrazeption. Frauenarzt 2003; 44: 1270-3
9. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998; 57: 103-9 (Pubitemid 28208481)
10. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara-). Clin Drug Investig 2002; 22: 221-31
11. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67: 305-12 (Pubitemid 36398516)
12. Zahradnik HP. Belara-: a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care 2005; 10 Suppl. 1: 12-8
13. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive: the Contraceptive Switch Study. Contraception 2007; 76: 84-90 (Pubitemid 47080979)
14. Schramm GAK, Waldmann-Rex S. Effects of 2 mg chlormadinone acetate/0.03 mg ethinylestradiol in primary dysmenorrhoea: the BEDY (Belara(R) Evaluation on Dysmenorrhea) study - an open non-comparative, noninterventional observational study with 4,842 women. J Reproduktionsmed Endokrinol 2010; 7: 112-8
15. Anthuber S, Schramm G, Heskamp M. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30: 211-20
16. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203: 38-44 (Pubitemid 32830529)
17. Beier HM, Beier-Hellwig K. Chlormadinonacetat: ein progesterona ̈hnliches Gestagen mit antiandrogener Partialwirkung in der oralen Kontrazeption. J Reproduktionsmed Endokrinol 2004; 1: 308-17 (Pubitemid 40126152)
18. Kerscher M, Reuther T, Bayrhammer J, et al. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups. Clin Drug Investig 2008; 28: 703-11
19. Luderschmidt C. Akne der Frau: eine interdisziplinäre Herausforderung. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierungserscheinungen. Stuttgart: Schattauer, 1995: 57-76
20. Ludwig M, Grave C, Hugo U. Orale Kontrazeptiva mit antiandrogen wirksamer gestagener Komponente. Frauenarzt 2006; 47 Suppl.: 1-14
21. Terlinden R, Uragg H, Göhler K, et al. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. Contraception 2006; 74: 239-44 (Pubitemid 44175357)
22. Huber JC, Heskamp ML, Schramm G. Effect of an oral contraceptive with chlormadinone acetate on depressive mood: analysis of data from four observational studies. Clin Drug Investig 2008; 28: 783-91
23. Heskamp ML, Schramm GA. Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits. Contraception 2010; 81: 49-56
24. Loudon NB, Foxwell M, Potts DM, et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ 1977; 2: 487-90 (Pubitemid 8245822)
25. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74: 439-45 (Pubitemid 46037535)
26. Foidart JM, Sulak PJ, Schellschmidt I, et al. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 2006; 73: 34-40 (Pubitemid 41811186)
27. Birkhäuser M, Braendle W, Breckwoldt M, et al. 24th Workshop of the ''Zürcher Gesprächskreis'' May 2000: commendations on oral contraception. Frauenarzt 2000; 41: 1053-8